1. Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma
   Jaishri O. Blakeley et al, 2019, Clinical Cancer Research CrossRef
2. Appraising iniparib, the PARP inhibitor that never was—what must we learn?
   Joaquin Mateo et al, 2013, Nature Reviews Clinical Oncology CrossRef
3. Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
   Xuesong Liu et al, 2012, Clinical Cancer Research CrossRef
4. Synthesis and cytotoxicity against KB and NCI-H187 cell lines of sporogen AO-1 analogues
   Chittreeya Tansakul et al, 2017, Phytochemistry Letters CrossRef
5. A review of iniparib in ovarian cancer
   Ivy Wilkinson-Ryan et al, 2013, Expert Opinion on Investigational Drugs CrossRef